LL37 Peptide: The Complete Guide - Uses, Mechanism, Dosing, Safety & Research

Quick Facts

What LL37 Does & How It Works

What It Does - Functional Outcomes

• Kills bacteria - including antibiotic-resistant strains like MRSA and Pseudomonas - by punching holes in their cell membranes
• Disrupts fungal cell membranes in organisms including Candida albicans
• Neutralizes bacterial endotoxins (LPS) that would otherwise trigger septic shock-level inflammatory responses
• Recruits neutrophils, monocytes, macrophages, and T cells to sites of infection through direct chemotaxis
• Accelerates skin wound healing by signaling skin cells to migrate toward the wound edge and triggering new blood vessel growth
• Modulates inflammatory responses - capable of both amplifying and dampening inflammation depending on the immune context
• Inactivates enveloped viruses including herpes simplex virus, influenza, and HIV in laboratory studies
• Disrupts bacterial biofilms, which is one of its more clinically significant potential advantages over conventional antibiotics
• Serves as the downstream effector of vitamin D's immune-supporting effects

How It Works - Mechanism of Action

Membrane Disruption and Bacterial Killing (Evidence: In vitro - well-established mechanistic literature)

LL37 carries a net positive charge of approximately +6 at physiological pH, which draws it electrostatically toward the negatively charged membranes of bacteria. Once it contacts a bacterial membrane, LL37 adopts an amphipathic alpha-helical shape - one face hydrophobic, one face hydrophilic - and inserts into the membrane. The most supported model for what happens next is called the toroidal pore model: LL37 molecules curve the membrane around themselves, forming pores that disrupt membrane integrity, depolarize the bacterium, and cause leakage of cellular contents. The result is bacterial cell death. The same basic mechanism applies to fungal cell membranes and the lipid envelopes of many viruses.

Immunomodulatory Signaling (Evidence: In vitro and human mechanistic data)

LL37 binds to a receptor called formyl peptide receptor-like 1 (FPR2 / FPRL1), found on neutrophils, monocytes, and dendritic cells. This binding triggers chemotaxis - the directional migration of immune cells toward the signal source. LL37 also activates P2X7 receptors and has context-dependent effects on Toll-like receptor signaling: it can activate TLR pathways in some settings and suppress LPS-driven TLR4 activation in others. In macrophages stimulated by bacterial LPS, LL37 reduces production of pro-inflammatory cytokines including TNF-alpha and IL-6, partly through inhibition of NF-kappaB signaling. The net immunomodulatory effect is context-dependent and not reducible to a simple pro- or anti-inflammatory label.

Wound Healing via EGFR Transactivation (Evidence: In vitro and animal models)

LL37 activates epidermal growth factor receptor (EGFR) - the main growth and repair switch in epithelial tissue - through an indirect mechanism. Rather than binding EGFR directly, LL37 triggers metalloprotease enzymes on the cell surface to shed EGFR ligands, which then activate the receptor. This indirect EGFR activation drives phosphorylation of ERK1/2 and Akt, two intracellular signaling proteins that promote cell survival, proliferation, and directional migration. In keratinocyte studies, this translates into accelerated movement of skin cells toward a wound edge. In animal wound models, it translates to faster re-epithelialization - the regrowth of surface skin over a wound.

CAMP Gene Regulation by Vitamin D (Evidence: Human macrophages and epidemiological data - Liu et al., 2006)

The gene encoding LL37's precursor protein, CAMP, contains a vitamin D response element in its promoter region - essentially a molecular binding site for activated vitamin D. When the active form of vitamin D (calcitriol) binds to its receptor in immune cells and epithelial cells, it directly increases transcription of the CAMP gene, which increases production of hCAP18, which is then cleaved to release LL37. This makes vitamin D status a direct upstream regulator of LL37 levels in tissue. Low vitamin D means less LL37. Restoring vitamin D in deficient individuals restores LL37 production.

Psoriasis Autoimmune Cascade (Evidence: Human psoriatic tissue - Lande et al., 2007)

In damaged psoriatic skin, LL37 released from neutrophils forms stable complexes with self-DNA and self-RNA released from dying cells. These LL37-nucleic acid complexes are taken up by plasmacytoid dendritic cells through endosomal TLR7 and TLR9 pathways, triggering a cascade of type I interferon production that drives and sustains chronic psoriatic inflammation. Separate work confirmed that T cells in psoriatic skin are directly reactive to LL37 as a self-antigen - meaning the immune system has become sensitized to a molecule the body produces itself. This makes LL37 one of a small number of human peptides that function simultaneously as a host defense molecule and a confirmed autoantigen in a common inflammatory disease.

LL37 Molecular Profile

Structure reference: View LL37 on PubChem - Publishing team: retrieve 2D structure image from this link.

Note on structure: LL37 exists as a random coil in aqueous solution and adopts its active amphipathic alpha-helical conformation when it contacts hydrophobic environments such as bacterial membranes. The helical structure is not visible in standard 2D structural representations, which depict the linear sequence only.

LL37 Uses & Benefits

Antimicrobial Applications - Bacteria, Fungi, and Biofilms

LL37 is studied as a potential antimicrobial agent for situations where conventional antibiotics fail - primarily antibiotic-resistant bacterial infections and biofilm-associated infections. Its membrane disruption mechanism does not depend on the enzymatic targets that most antibiotics block, which is why bacteria develop resistance to it much more slowly than to conventional antibiotic classes. In vitro studies have documented activity against MRSA, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Candida albicans, among many others. Biofilm disruption at concentrations of 4-16 mcg/mL in laboratory models is a particularly studied application, since biofilms are a major contributor to treatment-resistant chronic infections. (Evidence: Moderate - extensive in vitro; limited animal models; no approved clinical formulation)

Wound Healing and Skin Repair

Chronic wound healing is one of the most actively researched clinical applications for LL37. Chronic wounds - diabetic ulcers, pressure sores, venous ulcers - often show reduced LL37 expression in tissue, and this deficiency may contribute to impaired healing. Topical LL37 application has accelerated wound closure in multiple diabetic and non-diabetic rodent wound models through the EGFR-keratinocyte migration pathway and VEGF-driven angiogenesis. The main barrier to translation is practical: the protease-rich, high-inflammatory environment of chronic wounds rapidly degrades native LL37 before it can act, which has driven development of hydrogel and nanoparticle delivery systems designed to protect the peptide. (Evidence: Moderate - multiple animal models, ex vivo human skin data; human clinical trials limited)

Innate Immunity and Vitamin D Axis

The most accessible LL37-related intervention for most people is not exogenous LL37 administration but the vitamin D-to-LL37 pathway. Maintaining adequate vitamin D status directly supports endogenous LL37 production through the CAMP gene promoter. This has been demonstrated in human immune cells and is the mechanistic basis for the observed correlations between vitamin D deficiency, reduced LL37 expression, and increased susceptibility to infections including tuberculosis and respiratory viruses. Vitamin D supplementation in deficient individuals restores LL37 levels and has been shown to enhance macrophage killing of tuberculosis bacteria in human studies. (Evidence: Strong for the mechanistic pathway - human data; Mixed for clinical outcome benefit in supplementation trials)

Antiviral Defense

LL37 has documented antiviral activity against several clinically important viruses in laboratory studies. The mechanism involves direct disruption of viral lipid envelopes for enveloped viruses and interference with viral attachment to host cell receptors. Confirmed in vitro activity exists against herpes simplex virus types 1 and 2, HIV, influenza, respiratory syncytial virus, and vaccinia virus. Preclinical studies examining LL37's activity against SARS-CoV-2 generated interest during the COVID-19 pandemic, partly in the context of the vitamin D-LL37-antiviral immunity hypothesis. These findings remain in vitro; no clinical antiviral application has been established. (Evidence: Preliminary to Moderate - in vitro; no approved antiviral clinical application)

Psoriasis Research - Understanding a Paradox

LL37's role in psoriasis is the inverse of most research applications: rather than being the therapeutic target, LL37 is being studied as the pathological driver to block. The mechanistic work establishing LL37 as a psoriasis autoantigen and the initiator of the pDC-interferon cascade has opened research into anti-LL37 antibodies and TLR7/TLR9 pathway inhibitors as potential psoriasis treatments. This reversal - researching how to reduce LL37 activity rather than increase it - is one of the most clinically significant outcomes of the LL37 research base and has direct implications for anyone with psoriasis considering exogenous LL37. (Evidence: Strong for mechanism in human psoriatic tissue - Lande et al., 2007)

Where This Guide Comes From

LL37 Results & Timelines

LL37 is not widely used as an exogenous research compound by individual users, and the timeline data that exists comes primarily from preclinical studies rather than the kind of documented human protocol logs that populate this section for most peptides. What follows represents the timelines from published research models and the limited practitioner and community documentation that exists, clearly labeled by source.

Wound Healing and Skin Repair

• First 48-72 hours: In animal wound models, increased keratinocyte migration toward wound edges is measurable within this window following topical LL37 application. Whether this has any perceptible correlate in humans has not been established.
• Week 1-2: The clearest effects in rodent wound healing studies appear in this window - re-epithelialization rates diverge meaningfully from untreated controls, with LL37-treated wounds showing consistently faster surface coverage.
• Week 2-3: Full wound closure in animal models accelerated relative to controls; VEGF-driven angiogenesis contributes to deeper tissue repair in this phase.
• Beyond 3 weeks: Most animal wound healing studies end at wound closure rather than following a fixed timeline; long-term scar or tissue quality data is less consistent.

Antimicrobial Effects

• Minutes to hours: Direct membrane disruption and bacterial killing in in vitro settings occurs within this window at effective concentrations. This is a laboratory observation rather than a clinical timeline.
• In biofilm models: Biofilm disruption in Staphylococcus aureus and Pseudomonas models required sustained exposure at active concentrations over 24-48 hours in most published studies.

Vitamin D-Mediated LL37 Upregulation

• Week 1-2: CAMP gene transcription increases measurably following initiation of vitamin D supplementation in deficient individuals in published mechanistic studies.
• Week 4-8: Circulating LL37 levels and macrophage antimicrobial function improvements in deficient populations supplementing vitamin D appear in this range in published studies, though this varies substantially with baseline deficiency severity and dose.

How to Administer LL37

Topical

Topical application is the most extensively studied route for LL37 in research and the one with the most practical rationale for potential therapeutic use. In wound healing studies, LL37 is applied directly to the wound surface in solution, gel, or hydrogel formulations. The key challenge with topical LL37 is the proteolytic activity in wound environments - serine proteases in wound exudate can degrade native LL37 within minutes to hours, substantially limiting how much active peptide reaches target cells. This is why most current wound healing research uses LL37 embedded in protective delivery matrices (hydrogels, cellulose dressings, nanoparticle formulations) rather than naked peptide in solution. Penetration through intact, healthy skin is limited; the clinical scenario where topical application makes sense is damaged or diseased skin, not intact skin.

Intramuscular Injection (IM) and Subcutaneous Injection (SubQ)

SubQ and IM routes have been used in animal model studies for systemic delivery. Significant protease activity in subcutaneous tissue and blood subjects LL37 to rapid degradation, limiting the duration of active peptide in circulation. These routes are not used in human clinical investigation for native LL37, and the stability challenges make them suboptimal for the native peptide without formulation protection. Some practitioners have documented use of LL37 via injection for wound healing purposes, but no human clinical trial data supports this approach with native LL37.

Intranasal and Nebulized Delivery

Intranasal and nebulized delivery has been studied for respiratory applications - particularly for lung infections and cystic fibrosis research, where LL37 deficiency in airway surface liquid is a documented component of impaired lung defense. Nebulized delivery achieves meaningful local concentrations in airway mucosa with limited systemic absorption, which is a relative safety advantage. Mucosal proteases still limit the active peptide window, and sustained delivery systems for airway applications remain in research stages.

Oral

Oral administration is not effective for systemic or antimicrobial purposes. Native LL37 is degraded by the proteolytic enzymes in the gastrointestinal tract - pepsin, trypsin, chymotrypsin - before reaching systemic circulation in any meaningful concentration. The body does naturally produce LL37 in gut epithelial cells as a local innate defense mechanism, but this endogenous production is a local process entirely separate from swallowing exogenous peptide. No oral formulation of native LL37 has demonstrated systemic bioavailability in published research.

LL37 Dosage & Cycle Length

A clear note before this section: LL37 has no established human dosing protocol. None. The concentrations below come entirely from published preclinical research - in vitro cell studies and animal models. This is not a situation where the research community has settled on a broad therapeutic range that practitioners then adapt. Exogenous LL37 administration in humans is investigational, the clinical trial landscape is thin, and the safety profile at systemic concentrations presents real constraints. This section documents what the published research uses - not a framework for human self-administration.

In vitro concentration spectrum:

• Antimicrobial assays: 1-16 mcg/mL (minimum inhibitory concentration range for susceptible organisms)
• Immunomodulatory studies: 0.1-10 mcg/mL (concentrations used to study receptor activation and cytokine modulation)
• Therapeutic window in vitro: approximately 1-10 mcg/mL (range where antimicrobial effect is present without significant mammalian cell cytotoxicity)
• Cytotoxic threshold in mammalian cells: generally above 25 mcg/mL, though this varies by cell type

Animal model dosing (topical applications):

• Wound healing models: 1-10 mcg per wound site in mouse models
• Typical application frequency in animal studies: once daily to every 48 hours

Animal model dosing (systemic administration):

• Exploratory infection models: 1-5 mg/kg in rodents
• Hemolytic effects in rodents documented at IV doses above approximately 10 mg/kg - this ceiling is a direct safety constraint on systemic dose escalation

Cycle length context: Most preclinical LL37 studies involving topical application run 7-21 days. Longer-duration data is sparse. No established on/off cycling pattern exists because no therapeutic protocol has been validated in humans. Studies examining wound healing in animal models typically follow the wound through closure rather than using a fixed time cycle.

LL37 analogs - an important distinction: Most current clinical trial activity does not use native LL37. Modified analogs - GF-17, P60.4Ac, 17BIPHE2, and others - have been developed specifically to address native LL37's stability problems, salt sensitivity, and hemolytic risk. These analogs have entered early clinical investigation for wound care and antimicrobial applications. If you encounter dosing data attributed to LL37 in clinical trial contexts, confirm whether it refers to native LL37 or an engineered analog, as the two are not interchangeable.

LL37 Vial Sizes, Costs & Quality

Common vial sizes: LL37 is available from research peptide suppliers in 1 mg, 5 mg, and 10 mg vials. Smaller vial sizes (1 mg) reflect the research context - per-milligram quantities are sufficient for in vitro and small animal work, and the compound is expensive to synthesize.

Typical cost range: $80-$200 per milligram for U.S.-manufactured research-grade LL37 is a reasonable market estimate, though pricing varies significantly based on purity specification, vial size, and supplier. Larger vial sizes offer lower per-milligram pricing. LL37 is one of the more expensive peptides in research contexts because the 37-amino acid chain requires more synthesis steps and more purification work than shorter peptides.

Storage - lyophilized (dry powder):

• Temperature: Store at -20 degrees C; stable at this temperature for 12-24 months when properly sealed
• Light sensitivity: Protect from light; store in the dark when not in use
• Handling: Minimize freeze-thaw cycles to preserve peptide integrity

Storage - reconstituted (in solution):

• Temperature: Refrigerate at 2-8 degrees C immediately after reconstitution
• Use window: 7-14 days once reconstituted - shorter than many peptides due to LL37's susceptibility to protease degradation and aggregation over time
• Reconstitution solvent: Sterile water, phosphate-buffered saline (PBS), or 0.1% acetic acid depending on manufacturer specifications; check the certificate of analysis for the specific product

Normal appearance after reconstitution: LL37 reconstitutes to a clear, colorless to slightly pale solution at typical research concentrations. At higher concentrations, the peptide can self-aggregate and the solution may become slightly hazy. Mild haze at high concentration is documented behavior for LL37 and may not indicate degradation, but a solution that was previously clear and becomes hazy or shows visible particulates on storage should not be used.

Signs of degradation: Visible particulates or chunky material that does not dissolve with gentle agitation, significant discoloration (yellow or brown tint), or a solution that becomes gel-like or viscous beyond normal handling. Degraded LL37 should not be used.

Quality Considerations

LL37 is synthesized through solid-phase peptide synthesis, and the 37-amino acid chain means that synthesis quality genuinely matters in a way that shorter peptides sometimes escape. Each coupling step in synthesis introduces a small risk of incomplete reaction, deletion sequences, and racemization - by step 37, those small risks compound into measurable impurity profiles if the synthesis process is not tightly controlled. A product listed at 95% purity by HPLC has 5% of something else in the vial, and with a 37-residue peptide, that 5% could include truncated sequences or modified variants with unpredictable activity. Overseas suppliers selling LL37 at prices substantially below the synthesis cost of a legitimate 95%+ HPLC-pure product are selling something - but a certificate of analysis from an unverified lab is worth what you paid to check it. U.S.-manufactured research peptides come with synthesis documentation, third-party HPLC purity testing, and mass spectrometry confirmation that the correct molecular weight was achieved. For a compound with LL37's complexity and research cost, that paper trail is not a luxury.

LL37 Side Effects & Safety

Side Effect Spectrum

Contraindications

• Active psoriasis or personal/family history of psoriasis: LL37 is mechanistically implicated in the psoriatic autoimmune cascade. Exogenous LL37 administration in individuals with active psoriasis or genetic predisposition carries a genuine risk of worsening or triggering flares.
• Active systemic lupus erythematosus (SLE): LL37-DNA complexes are a documented driver of the type I interferon production that sustains SLE. Administration in active SLE is contraindicated on mechanistic grounds.
• Rosacea (active): Aberrant LL37 processing is implicated in rosacea pathogenesis; additional exogenous LL37 may worsen the condition.
• Active malignancy - particularly ovarian cancer, lung cancer, or thyroid cancer: LL37 has documented pro-tumorigenic activity in these cancer types via EGFR and FPR2 signaling. Use in these contexts is not supported.
• Known hypersensitivity to LL37 or cathelicidin peptides: Insufficient safety data to support use.

Populations Where Caution Is Warranted

• Pregnancy and breastfeeding: Insufficient safety data for exogenous LL37 administration; use is not recommended without medical supervision. Note: LL37 is naturally present in breast milk as a component of innate immune defense.
• Pediatric use: Not studied in pediatric populations; not appropriate without medical supervision.
• Personal or family history of autoimmune conditions (beyond those listed above): Given LL37's broad immunomodulatory effects, individuals with rheumatoid arthritis, inflammatory bowel disease, or other autoimmune conditions should approach exogenous LL37 with caution and medical oversight.
• Individuals with known vitamin D dysregulation: LL37 production is tightly regulated by vitamin D status; disrupting this balance with exogenous peptide may have unpredictable effects on the endogenous regulatory axis.

Red Flags - Stop Use and Seek Medical Attention If:

• Signs of systemic hemolytic reaction: rapid onset pallor, dark urine, fatigue, or jaundice following administration
• New or worsening psoriatic lesions, rosacea flares, or signs of autoimmune exacerbation following use
• Significant swelling, pain, warmth, or hardening at application or injection sites beyond normal transient irritation
• Any signs of systemic inflammatory or allergic reaction: fever, rash, difficulty breathing, widespread urticaria

Drug and Compound Interactions

No formal drug interaction studies for exogenous LL37 have been published in human clinical contexts. Theoretical interactions worth noting: compounds that modulate TLR signaling or NF-kappaB pathways - including certain immunosuppressants, corticosteroids, and other immunomodulatory peptides - may have additive or antagonistic effects on LL37's immunomodulatory activity. Concurrent use of vitamin D in high doses alongside exogenous LL37 may amplify LL37 production pathways; the clinical relevance of this interaction is unclear but documented at a mechanistic level. Given LL37's context-dependent immunomodulatory profile, concurrent use with immunosuppressive therapy for autoimmune conditions warrants specific medical oversight.

LL37 Research & Studies

Pharmacokinetics & Metabolism

Absorption & Bioavailability

Topical LL37 absorption through intact skin is limited; penetration through damaged, inflamed, or wound tissue is more substantial but highly variable depending on the delivery system used. Systemic bioavailability via topical application to healthy skin is low - a limitation for systemic antimicrobial applications but a relative safety feature for topical wound use. Intranasal and nebulized delivery achieves local airway mucosal concentrations with limited systemic exposure due to mucosal proteolysis. Parenteral administration achieves systemic distribution but subjects the peptide to serum proteolytic degradation that limits the active window substantially.

Distribution

Endogenously, LL37 is concentrated in secondary granules of neutrophils and released at sites of infection and inflammation. Exogenously administered LL37 in animal models distributes to sites of active inflammation following parenteral administration, consistent with its net cationic charge and the altered surface charge properties at inflammatory sites. Blood-brain barrier crossing has not been established for LL37, and CNS distribution should not be assumed.

Half-Life

LL37 has a short half-life in physiological conditions, estimated at minutes to approximately 1-2 hours in the presence of serum proteases. This rapid degradation is a primary challenge for therapeutic development and is why native LL37 is generally not considered viable for systemic administration without either formulation protection or structural modification. Half-life in wound fluid is similarly constrained by the high protease activity characteristic of chronic wound environments.

Metabolism & Elimination

LL37 is cleaved by serine proteases including kallikreins, proteinase 3, and neutrophil elastase - the same enzymes involved in processing hCAP18 to release LL37 endogenously. This creates the unusual situation where the enzymes that generate LL37 also degrade it once released. Elimination of degradation products follows standard peptide catabolism pathways. Specific renal elimination data for LL37 fragments is not well characterized in published literature.

Note on data gaps: Formal human pharmacokinetic studies for exogenous LL37 do not exist in the published literature as of July 2026. The half-life and distribution data above are extrapolated from in vitro serum stability studies and animal pharmacology. This is a significant gap in the knowledge base.

Mechanistic Research

Membrane Disruption and Bacterial Killing (Evidence: In vitro - well-established mechanistic literature)

The toroidal pore model for LL37's antimicrobial mechanism has been characterized through a combination of membrane model studies, nuclear magnetic resonance (NMR) structural analysis, and electron microscopy. Studies comparing LL37 to synthetic analogs have established which structural features - particularly the amphipathic helical configuration and cationic charge density - are required for membrane activity. The minimum helical segment required for antimicrobial activity is approximately 20-24 amino acids, as demonstrated through truncation studies. These mechanistic foundations are not controversial and represent established biochemical knowledge.

Psoriasis Autoimmune Cascade (Evidence: Human - landmark mechanistic studies - Lande et al., 2007)

Lande and colleagues demonstrated that LL37 forms complexes with self-DNA and self-RNA released from damaged skin cells - what immunologists call danger-associated molecular patterns. These LL37-DNA complexes are taken up by plasmacytoid dendritic cells through endosomal TLR7 and TLR9 pathways, producing a robust type I interferon cascade that drives the chronic autoimmune inflammation of psoriasis. Subsequent work confirmed that T cells in psoriatic skin are directly reactive to LL37 as a self-antigen. This makes LL37 genuinely unusual: it is both a component of normal host defense and a confirmed autoantigen in a common inflammatory disease.

Vitamin D Regulation of CAMP Gene Expression (Evidence: Human macrophages and epidemiological data - Liu et al., 2006)

Liu and colleagues published work in Science demonstrating that 1,25-dihydroxyvitamin D3 (calcitriol) directly activates CAMP gene transcription in human monocytes and macrophages via a vitamin D response element in the gene's promoter region. The same study showed that vitamin D-induced LL37 production enhanced killing of Mycobacterium tuberculosis inside macrophages. This work provided a mechanistic explanation for epidemiological observations linking low vitamin D status to tuberculosis susceptibility and established the vitamin D-LL37 pathway as a therapeutically targetable axis through vitamin D supplementation rather than exogenous LL37.

EGFR Transactivation and Wound Healing Signaling (Evidence: In vitro and animal models)

Mechanistic studies have shown that LL37 activates EGFR through a transactivation mechanism involving metalloprotease-mediated shedding of EGFR ligands rather than direct receptor binding. This indirect EGFR activation drives downstream phosphorylation of ERK1/2 and Akt - signaling proteins that promote cell survival, migration, and proliferation. In keratinocyte culture studies, LL37-induced EGFR activation stimulates directional migration toward wound edges. The same EGFR activation pathway is one of the mechanisms implicated in LL37's pro-tumorigenic activity in certain cancer types, illustrating the mechanistic overlap between regenerative and tumor-promoting biology.

Condition-Focused Research

Wound Healing and Skin Repair {#research-wound}

Multiple animal model studies have established that topical LL37 accelerates wound closure in diabetic and non-diabetic rodent wound models, with re-epithelialization rates consistently higher than untreated controls. An ex vivo human skin model study demonstrated that LL37 at 10 mcg/mL stimulated keratinocyte migration inhibitable by EGFR blockers, confirming the EGFR pathway's role. A key limitation across this body of research is that the efficacy seen with native LL37 in controlled laboratory conditions does not straightforwardly translate to the protease-rich environment of chronic wounds in living patients - an issue that has driven the shift toward protected delivery systems in more recent work. (Evidence: Moderate - multiple animal models, ex vivo human data; human clinical trial data limited)

Antimicrobial Activity Against Resistant Pathogens {#research-antimicrobial}

In vitro studies have established minimum inhibitory concentrations for LL37 against a broad range of clinically important organisms including MRSA, Pseudomonas aeruginosa, and Klebsiella pneumoniae. A consistent finding across this literature is that antimicrobial activity is substantially reduced in the presence of physiological salt concentrations (approximately 150 mM NaCl) - a finding with direct relevance to therapeutic application, since bodily fluids are isotonic. This salt sensitivity is one of the primary drivers of analog development; engineered variants like WLBU2 maintain activity in high-salt conditions where native LL37 does not. In biofilm disruption studies, LL37 at 4-16 mcg/mL disrupted established Staphylococcus aureus and Pseudomonas biofilms in in vitro models - an application where conventional antibiotics often fail. (Evidence: Moderate - extensive in vitro; animal biofilm models; no approved clinical formulation - Mookherjee et al., 2020)

Tuberculosis and Macrophage Immunity {#research-tb}

The Liu et al. 2006 study in human macrophages remains the foundation of the LL37-tuberculosis research story. Subsequent work has confirmed the vitamin D response element in the CAMP promoter through molecular biology studies and has correlated vitamin D deficiency with reduced LL37 expression in clinical populations. Epidemiological data from TB-endemic regions consistently shows lower vitamin D levels in active TB cases compared to exposed but uninfected controls. Clinical trials examining vitamin D supplementation in TB patients have shown mixed results, which suggests the vitamin D-LL37 axis is one component of tuberculosis susceptibility rather than the sole determinant. (Evidence: Moderate - human mechanistic data, epidemiological correlation; clinical trial outcomes mixed - Liu et al., 2006)

Psoriasis and Skin Autoimmunity {#research-psoriasis}

Lande et al.'s 2007 paper and subsequent work from multiple groups established a mechanistic model of psoriasis initiation in which LL37-DNA complexes serve as the initial trigger for plasmacytoid dendritic cell activation and type I interferon production. T cells isolated from psoriatic skin lesions and peripheral blood of psoriasis patients have been shown to proliferate specifically in response to LL37 antigen presentation, confirming LL37's status as a psoriasis autoantigen. This research has clinical translation implications in the opposite direction from most LL37 research: blocking the LL37-DNA complex formation or the TLR7/TLR9 pathway it activates is being explored as a therapeutic strategy for psoriasis. Anti-LL37 antibody approaches are in research stages. (Evidence: Strong for mechanism in human psoriatic tissue - Lande et al., 2007)

Rosacea and Cathelicidin Processing {#research-rosacea}

LL37's role in rosacea was clarified by research showing that abnormal kallikrein-5-mediated processing of hCAP18 in rosacea-affected skin produces specific LL37 fragments that activate TRPV4 ion channels and TLR2 pathways, driving the characteristic vascular inflammation and skin sensitivity. The finding is notable because it is not simply elevated LL37 that drives rosacea - it is abnormally processed LL37 fragments generated by dysregulated protease activity. This distinction matters for understanding why blocking LL37 production indiscriminately would not be an ideal therapeutic approach; the target is the aberrant processing, not LL37 itself. (Evidence: Moderate - human rosacea tissue studies - Zheng et al., 2007)

Safety & Tolerability Research

Formal safety and tolerability data for exogenous LL37 in humans is limited given the absence of approved therapeutic formulations. In vitro data establishes a therapeutic window between antimicrobial concentrations (1-10 mcg/mL) and hemolytic concentrations (typically above 20-100 mcg/mL), which is a reasonable therapeutic index for topical applications where systemic exposure is limited. Systemic administration in rodents at doses above 10 mg/kg IV produces hemolytic and organ toxicity effects, setting a ceiling on systemic dose escalation. The absence of long-term human safety data is a genuine limitation; the longest-duration human exposure data comes from very early-phase clinical investigations of LL37 analogs rather than native LL37. Paradoxically, LL37's endogenous presence in all healthy humans provides some baseline safety reassurance - the peptide is not foreign to human biology - but exogenous administration bypasses the tight regulatory control of endogenous production that keeps tissue concentrations within safe ranges.

Research Limitations

LL37's research base is extensive in volume but limited in clinical translation. The available evidence is heavily weighted toward in vitro mechanistic work and rodent models; published human clinical trials testing exogenous LL37 administration are sparse. Protease sensitivity and salt sensitivity under physiological conditions have prevented native LL37 from advancing through clinical development, meaning the most clinically advanced data uses modified analogs whose properties differ meaningfully from the native peptide. Long-term safety data for systemic administration does not exist in humans. The cancer biology is genuinely unresolved - pro-tumorigenic and anti-tumorigenic findings exist across different cancer types with no consensus on net clinical direction. The endogenous nature of LL37 also makes exogenous administration dosimetry difficult: supplementing a molecule the body already produces and tightly regulates introduces a physiological variable that conventional pharmacology models do not readily accommodate.

Is LL37 Legal? Regulatory & Sports Status

FDA status: LL37 is not approved by the FDA for any therapeutic indication. No LL37-based product holds an Investigational New Drug (IND) designation for human therapeutic use as of July 2026. LL37 analogs have progressed further in early clinical investigation, but native LL37 itself remains a research compound. Any use in human subjects in a clinical investigation context would require an IND application and approval before proceeding.

Research Use Only (RUO): In most countries, LL37 is classified as a research compound. It is legally available for purchase for legitimate laboratory and preclinical research purposes. It is not approved for human self-administration as a therapeutic agent, and suppliers are required to label products for research use only. The gap between legal research purchase and legal human use is significant - possession for personal use occupies a regulatory gray area in many jurisdictions, but no jurisdiction has approved LL37 for human therapeutic self-administration.

WADA / USADA status: LL37 is not specifically named on the WADA Prohibited List as of the most recently available list prior to March 2026. However, LL37's status is not straightforwardly cleared for athletes. WADA's Section S4 (Hormone and Metabolic Modulators) contains language covering non-approved substances used to modulate metabolic or immune function, and the catch-all provisions for substances with no approved governmental therapeutic use may apply. Athletes should not interpret the absence of a specific LL37 listing as clearance - the applicable provisions and their enforcement depend on the specific sport federation and testing context. The endogenous nature of LL37 creates a specific detection challenge: since all humans produce LL37, a simple presence test is not informative, and no validated method for distinguishing exogenous from endogenous LL37 has been published.

Country-specific notes: The European Medicines Agency has not approved any LL37-based therapeutic. Health Canada and Australia's TGA similarly have no approved LL37 products. In most jurisdictions, LL37 is not a scheduled substance but also not an approved pharmaceutical, placing it in a research-compound category. Users in any jurisdiction should verify current local regulations before purchase or use.

Detection: No validated anti-doping test for exogenous LL37 administration has been published. The endogenous nature of the peptide makes detection by simple presence methods impossible; distinguishing exogenous from endogenous LL37 would require isotope ratio methods or population-based reference range testing, neither of which has been established for LL37.

LL37 vs. Alternatives

Commonly Paired With - Synergistic Research Stacks

• LL37 + Vitamin D (calcitriol or cholecalciferol): The most evidence-supported combination in the LL37 literature. Vitamin D upregulates endogenous LL37 production through the CAMP gene promoter, and supplementing vitamin D is the primary practical strategy for increasing LL37 levels in deficient individuals. This is a well-characterized pathway in human biology rather than an experimental stack, and it is the most accessible LL37-related intervention for most people.
• LL37 + BPC-157 (research context): Some practitioner-facing literature discusses this pairing for wound healing applications, reasoning that LL37's antimicrobial and re-epithelialization effects combined with BPC-157's angiogenic and connective tissue support could address different components of wound healing simultaneously. This is not supported by published combination studies and remains speculative.
• LL37 + protected delivery systems (hydrogels, nanoparticles): Not a peptide combination but a formulation consideration. Native LL37 without delivery protection degrades rapidly in clinical environments; pairing it with an appropriate delivery matrix is effectively required for topical therapeutic application, and the current research frontier is largely about which delivery system works best for which tissue context.

Alternatives - When Another Compound May Be Considered

BPC-157 For wound healing applications where antimicrobial activity is not the primary concern, BPC-157 has a more established research base for connective tissue repair, angiogenesis, and growth factor upregulation with a better-characterized human safety profile. BPC-157 lacks LL37's direct antimicrobial mechanism, making it a complement rather than a replacement in infected wound contexts.

TB-500 (Thymosin Beta-4) TB-500 also promotes wound healing through actin dynamics and cell migration but operates through entirely different receptors and pathways from LL37. It has no meaningful antimicrobial activity. For pure tissue repair goals without infection concerns, TB-500 is a better-studied option for human use than exogenous LL37.

Defensins and other antimicrobial peptides (research context) Human beta-defensins and alpha-defensins are the other major category of endogenous antimicrobial peptides. They share some functional overlap with LL37 but have different structural classes (beta-sheet rather than alpha-helix), different receptor interactions, and somewhat different microbial spectra. Research interest is comparable but clinical translation is similarly early-stage.

Conventional antibiotics For approved human therapeutic use in infectious disease, conventional antibiotics remain the standard of care. LL37's antimicrobial research interest is greatest for contexts where conventional antibiotics fail - antibiotic-resistant organisms and biofilm infections - rather than as a replacement for proven therapies in general clinical practice.

Comparison table:

Build Your LL37 Protocol

FAQs

What is LL37?

LL37 is the only antimicrobial peptide of the cathelicidin family that the human body naturally produces. Made up of 37 amino acids, it is derived from a precursor protein called hCAP18 and is found in immune cells, skin, the respiratory tract, and other mucosal surfaces throughout the body. As a research compound, it is studied for its ability to kill bacteria and viruses, modulate immune responses, and accelerate wound healing.

What does LL37 do?

LL37 performs multiple functions simultaneously: it disrupts bacterial and fungal cell membranes, neutralizes bacterial endotoxins that can cause septic shock-level inflammatory responses, recruits immune cells to sites of infection, accelerates wound healing by activating skin cell migration and new blood vessel growth, and modulates the inflammatory response depending on the immune context. It also has documented antiviral activity against enveloped viruses in laboratory studies. The breadth of these effects makes it one of the most studied peptides in innate immunity and antimicrobial resistance research.

How long does LL37 take to work?

In preclinical research, LL37's direct antimicrobial effects are rapid - membrane disruption occurs within minutes to hours at effective concentrations. Wound healing acceleration in animal models becomes measurable within 48-72 hours and shows significant effects at the 2-week mark. These timelines come from controlled research settings, and no clinical timeline data exists for human therapeutic use since LL37 is not approved for that purpose.

What is the typical dose of LL37?

No established human dosing protocol exists for LL37. In vitro research uses concentrations of 1-10 mcg/mL for antimicrobial and immunomodulatory studies. Animal wound healing models typically apply 1-10 mcg per wound site. Human dosing has not been established through clinical trials, and the absence of validated human dosing is a meaningful consideration for anyone evaluating LL37. MyPeptidePal can help contextualize that picture given your specific situation and goals.

Is LL37 legal?

LL37 is legal to purchase for legitimate research purposes in most jurisdictions. It is not approved for human therapeutic use anywhere, and no jurisdiction has cleared it as a supplement or prescription drug. Athletes should note that while LL37 is not specifically named on the WADA Prohibited List, catch-all provisions for non-approved substances likely apply. Regulatory status varies by country, and users are responsible for understanding the rules in their location.

Can LL37 be taken orally?

No. Native LL37 is rapidly degraded by the proteolytic enzymes in the gastrointestinal tract before reaching systemic circulation in any meaningful concentration. The body does naturally produce LL37 in gut epithelial cells as a local innate defense mechanism, but that is an endogenous local process - not a parallel for swallowing exogenous peptide. No oral formulation of native LL37 has demonstrated systemic bioavailability in published research.

Does LL37 cause or worsen psoriasis?

Yes - this is one of the most important and counterintuitive aspects of LL37 biology. In psoriatic skin, LL37 forms complexes with self-DNA released from damaged cells, and these complexes activate the immune cascade that drives psoriatic inflammation. LL37 also functions as a confirmed autoantigen in psoriasis - the immune systems of psoriasis patients develop T cells that specifically react to LL37. Individuals with active psoriasis or a strong personal or family history of psoriasis should not use exogenous LL37; the risk of worsening or triggering flares is well-supported mechanistically.

What is the connection between vitamin D and LL37?

Vitamin D directly regulates LL37 production through a vitamin D response element in the CAMP gene promoter. When the active form of vitamin D binds to its receptor in immune cells and epithelial cells, it increases transcription of the gene that produces LL37's precursor protein. Research has demonstrated this pathway directly in human macrophages and shown that vitamin D supplementation in deficient individuals restores LL37 levels and improves macrophage killing of tuberculosis bacteria. Optimizing vitamin D status is the most evidence-supported strategy for supporting LL37 activity currently available.

Why is LL37 not already used as an antibiotic drug?

Several interconnected problems have prevented LL37 from becoming a clinical antibiotic despite decades of research. Its antimicrobial activity is substantially reduced in physiological salt concentrations, meaning effectiveness in body fluids is much lower than in the laboratory. It degrades rapidly in the presence of the serine proteases found in blood and tissue. At concentrations required for systemic antimicrobial effect, it carries hemolytic risk. And it is expensive to synthesize at clinical scale. These challenges have shifted most research toward engineered LL37 analogs designed to fix these specific problems rather than using the native peptide.

Is LL37 safe for people with autoimmune conditions?

Exogenous LL37 is specifically contraindicated in several autoimmune conditions. In psoriasis, rosacea, and systemic lupus erythematosus, LL37's documented biological mechanisms actively contribute to disease pathology - exogenous LL37 could worsen these conditions. More broadly, the same immunomodulatory effects that make LL37 interesting in research are a genuine safety concern for anyone whose immune system is already dysregulated. Anyone with an autoimmune condition should discuss LL37 with a qualified healthcare provider before any consideration of use.

Final Thoughts

LL37 is one of the most scientifically rich peptides in this library and one of the most complicated to interpret. It is the human body's only cathelicidin - a molecule that sits at the intersection of antimicrobial defense, immune signaling, wound repair, and, in certain contexts, autoimmune pathology. The research behind it is not thin. Thousands of published studies have characterized its mechanisms in detail, established its role in the vitamin D-immunity axis, confirmed its autoantigen status in psoriasis, and documented its wound healing signaling pathways in animal models and human tissue. What that research has not produced, yet, is an approved human therapeutic - and the reasons for that gap are scientifically substantive, not merely bureaucratic.

The honest context for anyone considering exogenous LL37 is this: the same biology that makes it compelling in research is the biology that makes it genuinely difficult to use safely. Protease degradation in physiological conditions limits delivery. Salt sensitivity reduces antimicrobial potency in body fluids. Hemolytic risk constrains systemic dosing. And the immunomodulatory breadth that makes LL37 a useful research tool creates real risk for individuals with autoimmune conditions, psoriasis, rosacea, or lupus - conditions where LL37 is part of the disease mechanism, not the solution. These are not minor technical footnotes. They are the core reasons the research community has largely shifted to LL37 analogs for clinical development rather than the native peptide. The regulatory status reflects scientific reality, not oversight inertia.

If LL37's biology intersects with your health goals - chronic wound healing, understanding your innate immunity, the vitamin D connection, antimicrobial research - MyPeptidePal can help you build context around what the evidence actually supports for your specific situation. The broad scientific picture is in this guide. What your individual protocol looks like, given your health history, your immune status, and your goals, is a different and more specific conversation.

References

1. Zanetti, M. (2004). Cathelicidins, multifunctional peptides of the innate immunity. Journal of Leukocyte Biology, 75(1), 39-48.

2. Lande, R., Gregorio, J., Facchinetti, V., Chatterjea, D., et al. (2007). Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature, 449(7162), 564-569.

3. Liu, P. T., Stenger, S., Li, H., Wenzel, L., et al. (2006). Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science, 311(5768), 1770-1773.

4. Mookherjee, N., Anderson, M. A., Haagsman, H. P., & Davidson, D. J. (2020). Antimicrobial host defence peptides: Functions and clinical potential. Nature Reviews Drug Discovery, 19(5), 311-332.

5. Zheng, Y., Niyonsaba, F., Ushio, H., Nagaoka, I., et al. (2007). Cathelicidin LL-37 induces the generation of reactive oxygen species and extracellular DNA traps in human mast cells, and is relevant to the pathogenesis of rosacea. Journal of Investigative Dermatology, 127(10), 2378-2384.

6. Vandamme, D., Landuyt, B., Luyten, W., & Schoofs, L. (2012). A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cellular Immunology, 280(1), 22-35.

Note: The research brief for this article confirmed that no verified source URLs with confirmed access were provided in the input. The references above are drawn from established LL37 primary literature. All DOI links and publication details should be independently verified by the editorial team before publication. Additional sources pending editorial review.